CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients

被引:28
|
作者
Mohammadzadeh, Adel [1 ]
Rad, Isa Abdi [2 ]
Ahmadi-Salmasi, Babak [3 ]
机构
[1] Urmia Univ Med Sci, Dept Immunol & Genet, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Dept Genet, Orumiyeh, Iran
[3] Urmia Univ Med Sci, Dept Neurol, Imam Khomeini Hosp, Orumiyeh, Iran
关键词
CTLA-4; PD-1; TIM-3; Multiple sclerosis; T-CELL-ACTIVATION; MULTIPLE-SCLEROSIS; ASSOCIATION; MECHANISMS; GALECTIN-9; INFECTION; PROMOTES; DISEASE;
D O I
10.1016/j.jneuroim.2018.08.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS), is an autoimmune disorder of central nervous system (CNS) characterized by inflammation and demyelination. Self-tolerance impairment is considered to be induced by a combination of inherited susceptibility and environmental agents. In this work, we demonstrate that a reduction in the comparative expression of well-known inhibitory receptors (i.e., CTLA-4, PD-1, and TIM-3) is importantly linked with MS patients compared to healthy controls. The relative expression of interested genes was performed on peripheral blood mononuclear cells (PBMCs), by using quantitative real time-PCR (qRT-PCR). Our data high-lighted the role of inhibitory receptors in the maintenance of immune homeostasis in autoimmune disease.
引用
收藏
页码:105 / 108
页数:4
相关论文
共 50 条
  • [31] Interleukin 15 upregulates the expression of PD-1 and TIM-3 on CD4+ and CD8+ T cells
    Hakim, Mohamad S.
    Jariah, Rizka O. A.
    Spaan, Michelle
    Boonstra, Andre
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 9 (03) : 10 - +
  • [32] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Qin, Shuang
    Xu, Linping
    Yi, Ming
    Yu, Shengnan
    Wu, Kongming
    Luo, Suxia
    MOLECULAR CANCER, 2019, 18 (01)
  • [33] Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma
    Hou, Kai
    Xu, Xiaohui
    Ge, Xin
    Jiang, Jiacen
    Ouyang, Fan
    BIOFACTORS, 2024, 50 (02) : 250 - 265
  • [34] Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28
    Koohini, Zohreh
    Hossein-Nataj, Hadi
    Mobini, Maryam
    Hosseinian-Amiri, Aref
    Rafiei, Alireza
    Asgarian-Omran, Hossein
    CLINICAL RHEUMATOLOGY, 2018, 37 (08) : 2063 - 2071
  • [35] Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma
    Zhang, Bo
    Zhou, You Lang
    Chen, Xinming
    Wang, Ziheng
    Wang, Qiuhong
    Ju, Fei
    Ren, Shiqi
    Xu, Ran
    Xue, Qun
    Wu, Qiong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 68 : 131 - 136
  • [36] Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
    Andrews, Lawrence P.
    Yano, Hiroshi
    Vignali, Dario A. A.
    NATURE IMMUNOLOGY, 2019, 20 (11) : 1425 - 1434
  • [37] Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
    Andrews, Miles C.
    Duong, Connie P. M.
    Gopalakrishnan, Vancheswaran
    Iebba, Valerio
    Chen, Wei-Shen
    Derosa, Lisa
    Khan, Md Abdul Wadud
    Cogdill, Alexandria P.
    White, Michael G.
    Wong, Matthew C.
    Ferrere, Gladys
    Fluckiger, Aurelie
    Roberti, Maria P.
    Opolon, Paule
    Alou, Maryam Tidjani
    Yonekura, Satoru
    Roh, Whijae
    Spencer, Christine N.
    Curbelo, Irina Fernandez
    Vence, Luis
    Reuben, Alexandre
    Johnson, Sarah
    Arora, Reetakshi
    Morad, Golnaz
    Lastrapes, Matthew
    Baruch, Erez N.
    Little, Latasha
    Gumbs, Curtis
    Cooper, Zachary A.
    Prieto, Peter A.
    Wani, Khalida
    Lazar, Alexander J.
    Tetzlaff, Michael T.
    Hudgens, Courtney W.
    Callahan, Margaret K.
    Adamow, Matthew
    Postow, Michael A.
    Ariyan, Charlotte E.
    Gaudreau, Pierre-Olivier
    Nezi, Luigi
    Raoult, Didier
    Mihalcioiu, Catalin
    Elkrief, Arielle
    Pezo, Rossanna C.
    Haydu, Lauren E.
    Simon, Julie M.
    Tawbi, Hussein A.
    McQuade, Jennifer
    Hwu, Patrick
    Hwu, Wen-Jen
    NATURE MEDICINE, 2021, 27 (08) : 1432 - +
  • [38] Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis
    Fleury, Michelle
    Belkina, Anna C.
    Proctor, Elizabeth A.
    Zammitti, Christopher
    Simms, Robert W.
    Lauffenburger, Douglas A.
    Snyder-Cappione, Jennifer E.
    Lafyatis, Robert
    Dooms, Hans
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (04) : 566 - 577
  • [39] Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
    De Silva, Pushpamali
    Aiello, Marco
    Gu-Trantien, Chunyan
    Migliori, Edoardo
    Willard-Gallo, Karen
    Solinas, Cinzia
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (01) : 31 - 41
  • [40] Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
    Mangsbo, Sara M.
    Sandin, Linda C.
    Anger, Kerstin
    Korman, Alan J.
    Loskog, Angelica
    Totterman, Thomas H.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (03) : 225 - 235